|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.
|
31552559 |
2020 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed systematic review and 2 meta-analyses to assess possible correlations between common plasminogen activator inhibitor (<i>PAI-1</i>) and <i>FXIII</i> polymorphisms and ischemic stroke in children.
|
31530188 |
2020 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibrinolytic agents including plasmin and plasminogen activators improve outcomes in acute ischemic stroke and thrombosis by recanalizing occluded vessels.
|
31529593 |
2019 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intravenous recombinant tissue plasminogen and endovascular mechanical thrombectomy could be considered as treatment for acute ischemic stroke during pregnancy unless high risks of hemorrhage or preterm labor are expected.
|
30268366 |
2019 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of the genetic polymorphisms of the plasminogen activator inhibitor type 1 (PAI-1) gene with the risk of ischemic stroke (IS) in subjects with type 2 diabetes mellitus (T2DM).
|
30160528 |
2018 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, plasminogen activators have become a crucial area for clinical investigation for their ability to recanalise occluded arteries in ischaemic stroke and to accelerate haematoma clearance in haemorrhagic stroke.
|
30507392 |
2018 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
High blood levels of α<sub>2</sub>-antiplasmin (a2AP), an ultrafast, covalent inhibitor of plasmin, have been linked in humans to increased risk of ischemic stroke and failure of tissue plasminogen activator (tPA) therapy.
|
27472428 |
2017 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
|
27793534 |
2017 |
|
Ischemic stroke
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, t-PA either directly or via plasmin, has been shown to not only have key roles in modulating astrocytes, neurons, microglia, and pericytes, but also to have profound effects in a number of CNS conditions, including ischaemic stroke, severe traumatic brain injury and also in neurodegenerative disorders.
|
28925023 |
2017 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest a synergic effect of plasminogen activator inhibitor and heterozygosity for MTHFR C677T on the pathogenetic mechanisms leading to ischaemic stroke in young people.
|
21903703 |
2011 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study investigated the hypothesis that the insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor type-1 gene affects the risk for ischemic stroke, since results concerning this association have been controversial.
|
17581326 |
2007 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether the 4G/5G polymorphism of plasminogen activator inhibitor type 1 (PAI-1) and the -7351 C/T polymorphism of tissue-type plasminogen activator (t-PA) are associated with ischemic stroke, we conducted a case-control study of 190 hospital cases of first-ever ischemic stroke and 185 community-based controls.
|
17689414 |
2007 |
|
Ischemic stroke
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
|
15630497 |
2005 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group.
|
11168509 |
2001 |